Etzer Darout Analyst Performance

Etzer Darout is a stock analyst at Barclays in the medical sector, covering 22 publicly traded companies. Over the past year, Etzer Darout has issued 21 stock ratings, including buy, hold, and sell recommendations. While full access to Etzer Darout's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Etzer Darout's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Analyst Ranking

Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat

Average Return

00.00% 12-Month ROI

Success Rate

00.00% Profitable Ratings

Total Ratings

40 Last 5 Years

Buy Recommendations

77.50% 31 Buy Ratings

Companies Covered

22 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	77.5%	31 ratings
Hold	17.5%	7 ratings
Sell	5.0%	2 ratings

Out of 40 total stock ratings issued by Etzer Darout at Barclays, the majority (77.5%) have been Buy recommendations, followed by 17.5% Hold and 5.0% Sell.

Best & Worst Calls

• Best Call

  0000.0%

  FTSV

  Nov 2019

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.
• Worst Call

  000.0%

  FTSV

  Feb 2020

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	95.5% of companies on NASDAQ	21 companies
NYSE	4.5% of companies on NYSE	1 company

Etzer Darout, an analyst at Barclays, currently covers 22 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 22 companies	100.0%

Etzer Darout of Barclays specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 14 companies	63.6%
PHARMACEUTICAL PREPARATIONS 4 companies	18.2%
MED - DRUGS 3 companies	13.6%
MED PRODUCTS 1 company	4.5%

Etzer Darout's Ratings History at Barclays

Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe

Start Date

End Date

All Ratings Strong Buy Buy Hold Sell Rating

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription

12-Month ROIUpgrade to All Access to use the All ROI Filter

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating	12-Month Price & ROI	Details
XNCR Xencor	9/17/2025	Initiated Coverage	$8.62	$6.00	Underweight	$0.00 00.00% ROI
MGNX MacroGenics	9/17/2025	Initiated Coverage	$1.47	$3.00	Overweight	$0.00 00.00% ROI
EXEL Exelixis	9/17/2025	Initiated Coverage	$39.14	$40.00	Equal Weight	$0.00 00.00% ROI
CTMX CytomX Therapeutics	9/17/2025	Initiated Coverage	$1.96	$3.50	Overweight	$0.00 00.00% ROI
ARVN Arvinas	9/17/2025	Initiated Coverage	$7.64	$16.00	Overweight	$0.00 00.00% ROI
TERN Terns Pharmaceuticals	9/17/2025	Initiated Coverage	$7.30	$15.00	Overweight	$0.00 00.00% ROI
SMMT Summit Therapeutics	9/17/2025	Initiated Coverage	$18.12	$13.00	Underweight	$0.00 00.00% ROI
SRRK Scholar Rock	9/17/2025	Initiated Coverage	$32.34	$45.00	Overweight	$0.00 00.00% ROI
PTGX Protagonist Therapeutics	9/17/2025	Initiated Coverage	$58.59	$72.00	Overweight	$0.00 00.00% ROI
MRUS Merus	9/17/2025	Initiated Coverage	$66.90	$112.00	Overweight	$0.00 00.00% ROI
KYMR Kymera Therapeutics	9/17/2025	Initiated Coverage	$48.78	$60.00	Overweight	$0.00 00.00% ROI
JANX Janux Therapeutics	9/17/2025	Initiated Coverage	$23.41	$47.00	Overweight	$0.00 00.00% ROI
CCCC C4 Therapeutics	9/17/2025	Initiated Coverage	$3.41	$8.00	Overweight	$0.00 00.00% ROI
IVA Inventiva	9/2/2025	Boost Price Target	$6.19	$13.00	Buy	$0.00 00.00% ROI
SRRK Scholar Rock	8/7/2025	Lower Price Target	$34.62	$45.00	Outperform	$0.00 00.00% ROI
TERN Terns Pharmaceuticals	5/13/2025	Lower Price Target	$2.93	$15.00	Outperform	$0.00 00.00% ROI
VERV Verve Therapeutics	4/15/2025	Boost Price Target	$5.07	$24.00	Buy	$0.00 00.00% ROI
IVA Inventiva	4/4/2025	Lower Price Target	$3.26	$9.00	Buy	$0.00 00.00% ROI
ARVN Arvinas	3/12/2025	Set Price Target	$8.51	$20.00	Outperform	$0.00 00.00% ROI
BNTX BioNTech	3/11/2025	Boost Price Target	$105.35	$143.00	Outperform	$0.00 00.00% ROI
ARVN Arvinas	2/12/2025	Reiterated Rating	$18.88	$82.00	Outperform	$0.00 00.00% ROI

Stock Forecasts and Research Tools

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.